Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104
NCT03413319 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3
Last updated 2019-12-03
Summary
The purpose of this study is to assess the long-term safety and tolerability of ABBV-8E12 in subjects with progressive supranuclear palsy (PSP).
Conditions
- Progressive Supranuclear Palsy (PSP)
Interventions
- DRUG
-
ABBV-8E12
Solution for infusion
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
AbbVie Inc. · AbbVie
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-04-17
- Primary Completion
- 2019-11-20
- Completion
- 2019-11-20
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications
NCT02082249 ·Status: COMPLETED ·Phase: PHASE3
-
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease
NCT04379050 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy
NCT04658199 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease
NCT04750226 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy
NCT02839642 ·Status: COMPLETED ·Phase: PHASE3
-
EMD 128130 for the Treatment of Parkinson's Disease
NCT00009048 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian Medications
NCT01960842 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy Study for Treatment of Dementia in Progressive Supranuclear Palsy
NCT00522015 ·Status: UNKNOWN ·Phase: PHASE2
-
Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients
NCT00203164 ·Status: COMPLETED ·Phase: PHASE3
-
A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment
NCT03374917 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of Parkinson Symptoms
NCT00296192 ·Status: COMPLETED ·Phase: PHASE2
-
RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY
NCT04937530 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP
NCT04008355 ·Status: COMPLETED ·Phase: PHASE2
-
Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease
NCT04380142 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease
NCT01479127 ·Status: COMPLETED ·Phase: PHASE2
-
An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advanced-Stage Parkinson's Disease
NCT00501969 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain
NCT01744496 ·Status: COMPLETED ·Phase: PHASE4
-
An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease.
NCT00594165 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Tolerability and Efficacy of AVP-786 for the Treatment of Disinhibition
NCT02534038 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease
NCT03033498 ·Status: COMPLETED ·Phase: PHASE1
-
A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease
NCT04658186 ·Status: COMPLETED ·Phase: PHASE2
-
An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease
NCT00599196 ·Status: COMPLETED ·Phase: PHASE3
-
An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's Disease
NCT00594386 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease
NCT06055985 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease
NCT00219284 ·Status: COMPLETED ·Phase: PHASE4